Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

New Spanish Biosimilars Education Materials for Patients and Health Care Providers

Oncology Practice Insider

The FDA released new educational materials in Spanish to help educate patients and health care providers about biosimilar medications. The agency published the Biosimilars Patient Materials webpage in Spanish  and developed a version in Spanish of the What is a Biosimilar? infographic, Biosimilars Basics infographic and the biosimilars consumer update to help educate patients and health care providers about these important types of medications used to treat conditions such as cancer, Crohn’s disease, colitis, rheumatoid arthritis, psoriasis, and more.

The new Spanish materials provide plain language information about biological medications and their relationship to biosimilar medications, as well as interchangeable biosimilars, the concepts of safety and effectiveness, and how biosimilar medications can benefit patients.

The FDA is committed to increasing awareness and understanding of biosimilar medications and we are continuing to work on developing additional educational materials for patients and health care providers. Read more.